GLSI Stock Chart & Stats
$18.23
$0.46(3.54%)
At close: 4:00 PM EDT
$18.23
$0.46(3.54%)
Day’s Range― - ―
52-Week Range$7.78 - $34.10
Previous Close$13.65
Volume133.07K
Average Volume (3M)125.36K
Market Cap
$223.26M
Enterprise Value$10.00T>
Total Cash (Recent Filing)$8.88M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.98
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding14,678,208
10 Day Avg. Volume141,668
30 Day Avg. Volume125,359
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)805.09
Price to Sales (P/S)0.00
P/FCF Ratio-28.69
Enterprise Value/Market Cap1.53M
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-15.76M
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.39
Revenue Forecast (FY)N/A
Greenwich LifeSciences News
GLSI FAQ
What was Greenwich LifeSciences’s price range in the past 12 months?
Greenwich LifeSciences lowest stock price was $7.78 and its highest was $34.10 in the past 12 months.
What is Greenwich LifeSciences’s market cap?
Greenwich LifeSciences’s market cap is $223.26M.
When is Greenwich LifeSciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Greenwich LifeSciences’s earnings last quarter?
Currently, no data Available
Is Greenwich LifeSciences overvalued?
According to Wall Street analysts Greenwich LifeSciences’s price is currently Overvalued.
Does Greenwich LifeSciences pay dividends?
Greenwich LifeSciences does not currently pay dividends.
What is Greenwich LifeSciences’s EPS estimate?
Greenwich LifeSciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Greenwich LifeSciences have?
Greenwich LifeSciences has 14,678,208 shares outstanding.
What happened to Greenwich LifeSciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Greenwich LifeSciences?
Currently, no hedge funds are holding shares in GLSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Greenwich LifeSciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GLSI Sentiment 86%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth $97.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
60.27%
12-Months-Change
Fundamentals
Return on Equity
-793.76%
Trailing 12-Months
Asset Growth
184.03%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Greenwich LifeSciences
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Technical Analysis
Ownership Overview
38.23% Insiders
3.73% Mutual Funds
0.01% Other Institutional Investors
53.03% Public Companies and
Individual Investors